Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.64 |
| ▸ | PFKP | Q01813 | 1/20 | 0.64 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.64 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.64 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907120 | 1.00 | MTOR (0.90) | MTORKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL393728 | 0.95 | MTOR (1.00) | MTORKCNH2 | |
| SCHEMBL393727 | 0.95 | MTOR (1.00) | MTORKCNH2 | |
| SCHEMBL289661 | 0.94 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL1219660 | 0.94 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL4914502 | 0.91 | MTOR (0.89) | MTOR | |
| SCHEMBL4914459 | 0.91 | MTOR (0.89) | MTOR | |
| SCHEMBL393876 | 0.88 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL393875 | 0.88 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL22449750 | 0.87 | MTOR (0.83) | MTORKCNH2PIK3CDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | MTOR 24/4885KCNH2 4538/4885PIK3CD 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.